<DOC>
	<DOCNO>NCT00392288</DOCNO>
	<brief_summary>Primary objective : To demonstrate efficacy ciclesonide , compare placebo , 80 μg twice daily ( BID ) 40 μg BID 12 week patient persistent asthma . Secondary objective : To assess safety tolerability ciclesonide .</brief_summary>
	<brief_title>Efficacy Safety Ciclesonide ( CIC ) Administered Twice Daily Pediatric Patients With Asthma .</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Ciclesonide</mesh_term>
	<criteria>History persistent bronchial asthma least 3 month prior screen ; For patient persistent bronchial asthma treat controller therapy : Documented use inhale steroid Singulair® 5mg daily ; For patient persistent bronchial asthma treat controller therapy : Patients may document use reliever therapy albuterol/salbutamol may untreated ; Morning Peak Expiratory Flow ( AM PEF ) ≤90 % predict value inclinic spirometry 6 hour withhold albuterol/salbutamol ; Only patient age 6 &lt; 12 year must force expiratory volume one second ( FEV1 ) ≥50 % ≤85 % predict normal 6 hour withhold albuterol/salbutamol Nocturnal awakening asthma require treatment albuterol/salbutamol 4 night last 7 day screen period ; Use 8 puffs/day albuterol/salbutamol 3 consecutive day within last 7 Upper low respiratory tract infection within 4 week prior screen screen period ; History lifethreatening asthma , include history significant hypercarbia ( pCO2 &gt; 45 mmHg ) , prior intubation , respiratory arrest , seizures result exacerbation asthma ; More 3 inpatient hospitalization emergency care visit due asthma exacerbation year prior screening ; Use injectable oral corticosteroid within one month prior screen , 3 burst ) within 6 month prior screen ;</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Bronchial Asthma</keyword>
</DOC>